Maria Patrizia Caldirola
Chief Executive Officer at ClanoTech AB
Network origin in Maria Patrizia Caldirola first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden.
1
| Holding Company | Pharmaceuticals: Major | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Statistics
International
| Sweden | 2 |
| Denmark | 2 |
Sectoral
| Consumer Services | 3 |
Operational
| Corporate Officer/Principal | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
| Founder | 1 |
Most connected contacts
| Insiders | |
|---|---|
| Yihai Cao | 3 |
- Stock Market
- Insiders
- Maria Patrizia Caldirola
- Company connections
